KVUE - Kenvue Health Price Target Chart
Kenvue Inc. (KVUE) leverages a powerful distribution network and brand loyalty inherited from its spin-off from J&J, generating revenue through the sale of global hygiene and over-the-counter medication lines. The market capitalization trend is recorded at 19.68. The company operates within a safe haven, as diversified supplies and the nature of its products eliminate the risks of international sanctions.
Analytical breakdowns for Kenvue Corp (KVUE)
- stock value and consensus price forecast:
- market capitalization statistics:
- issuer book value statistics:
- business debt structure and liquidity details:
Aggregate Debt to Equity Kenvue Inc.|KVUE - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Kenvue Health|KVUE - Company Aggregate Debts|Debts to Book Capitalization Kenvue Corp|KVUE - Company Long-Term Debt|Company Short-Term Loans and Borrowings Kenvue|Quick Liquidity Indicator kenvue.com
- company profitability and valuation multiples indicators:
KVUE - Net Profit|Projected Future Earnings Kenvue Inc.|KVUE - Price to Earnings Ratio|Future Price to Earnings Multiple Kenvue Inc|KVUE - Price/Earnings to Growth Ratio|Company Value to EBITDA Kenvue Corp|KVUE - Operating profit before deduction of amortization|Earnings per share for the last four quarters Kenvue|KVUE - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months kenvue.com|KVUE - Earnings growth in current year|Expected net earnings per share growth next year Kenvue Inc.
General company analysis:KVUE kenvue.com
Kenvue Inc. focuses on scaling consumer brands through operational optimization, leveraging high confidence in the revamped management team. The consensus price target trend reflects the weighted average expectation of institutional analysts regarding fair value, allowing investors to track shifts in market sentiment and avoid overpaying when purchasing the asset at local target peaks.
Competitors of Kenvue Inc.
Analyst Consensus Forecast haleon.com (HLN)|Verona Pharma - Consensus Target|Jyong Biotech Limited - Price Target Chart|LGND: Consensus Target|AMRX - Analyst Consensus Forecast|PRGO: Analyst Consensus Forecast|Average Forecast Price alvotech.com (ALVO)|Price Target Chart Liquidia|Galapagos N.V. - Forecast Levels Chart|Analyst Consensus Forecast ANIP|MNKD (Afrezza) - Fair Value Consensus|Analyst Consensus Forecast AMPH (Amphastar Pharmaceuticals)|Analyst Consensus Forecast pacira.com PCRX|SPRY - Price Target Chart|Fair Value Consensus TBPH (Theravance Biopharma Inc)|Aquestive Pharma (AQST) - Price Target Chart|Consensus Target scPharmaceuticals|TECX (Tectonic Therapeutic Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast tonixpharma.com|Consensus Target SXTC (China SXT Pharmaceuticals)|EPRX (eupraxiapharma.com) - Fair Value Consensus|Price Target Chart BioHarvest BHST|Invizyne (EXOZ) - Average Forecast Price|ORMP: Consensus Target|Entera Bio Ltd. - Analyst Forecast Prices|HYFT: Analyst Consensus Forecast|ABVC BioPharma Inc. - Fair Value Consensus|CPIX (Cumberland Pharma) - Analyst Consensus Forecast|Average Forecast Price Quantum BioPharma Corp QNTM|Price Target Chart FibroGen, Inc. (FGEN)|TELO (telomirpharma.com) - Fair Value Consensus|Price Target Chart Rani Therapeutics Holdings, Inc. RANI|Analyst Consensus Forecast Synergy CHC Corp. SNYR|Rallybio Corp. - Analyst Consensus Forecast|Average Forecast Price Lexaria Bioscience|Pulmatrix, Inc. (PULM) - Price Target Chart|Broker Consensus Forecast PTHL|Consensus Target APM|Price Target Chart LYRA|Consensus Target IBO (Impact BioMedical Inc)|Analyst Consensus Forecast tnfpharma.com (TNFA)|Analyst Consensus Forecast YCBD (cbdMD)|painreform.com (PRFX) - Average Forecast Price|CYTO: Consensus Target|Fair Value Consensus LIPO (Lipella Pharmaceuticals Inc)|OPTN: Analyst Consensus Forecast|PIRS - Analyst Median Target|Price Target Chart Procaps Group S.A.|Broker Consensus Forecast PTPI (petrospharma.com)|Analyst Consensus Forecast QLI|Consensus Target Acelyrin Inc. SLRN|TFF Pharma - Consensus Target
